GEN Exclusives

More »

GEN News Highlights

Back to Item »

Celgene Pays Epizyme $90M for Ex-U.S. Rights to Histone Methyltransferase Inhibitor

Deal gives Celgene license to lead DOT1L candidate and option to other HTM inhibitors.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?